Stock ALNEV NEOVACS
Add to a list
To use this feature you must be a member
Log inSign up

Financials NEOVACS Euronext Paris

Equities

ALNEV

FR001400HDX0

Biotechnology & Medical Research

End-of-day quote Euronext Paris
Other stock markets
 06:00:00 2024-02-04 pm EST 		5-day change 1st Jan Change
1.98 EUR -1.00% Intraday chart for NEOVACS -1.00% -1.00%
Apr. 30 Neovacs S.A. Reports Earnings Results for the Full Year Ended December 31, 2023 CI

Valuation

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Capitalization 1 - - - - - 0.000278
Enterprise Value (EV) 1 - - - - - -0.2362
P/E ratio - - - - - -
Yield - - - - - -
Capitalization / Revenue - - - - - 0 x
EV / Revenue - - - - - -0.44 x
EV / EBITDA - - - - - 0.13 x
EV / FCF - - - - - 0.46 x
FCF Yield - - - - - 217%
Price to Book - - - - - -
Nbr of stocks (in thousands) - - - - - 0.14
Reference price 2 16,240,000 4,640,000 2,416,000 40,000 336,000 2.000
Announcement Date 4/29/19 4/30/20 6/29/21 5/2/22 4/30/23 4/30/24
1EUR in Million2EUR
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Net sales 1 0.007 0.0952 0.031 0.0225 0.001112 0.5383
EBITDA 1 -13.02 -8.118 -3.437 -7.728 -6.294 -1.889
EBIT 1 -13.08 -8.175 -3.492 -7.828 -6.445 -6.908
Operating Margin -186,852.84% -8,590.87% -11,281.43% -34,725.65% -579,583.27% -1,283.24%
Earnings before Tax (EBT) 1 -13.56 -9.302 -6.684 -12.48 -4.346 -9.62
Net income 1 -10.78 -7.548 -6.143 -11.84 -3.549 -8.743
Net margin -154,006.91% -7,932.63% -19,846.4% -52,512.21% -319,109.98% -1,624.3%
EPS - - - - - -
Free Cash Flow 1 -11.26 -6.032 -2.054 -3.701 -3.496 -0.5115
FCF margin -160,809.06% -6,339.21% -6,635% -16,418.4% -314,371.22% -95.03%
FCF Conversion (EBITDA) - - - - - -
FCF Conversion (Net income) - - - - - -
Dividend per Share - - - - - -
Announcement Date 4/29/19 4/30/20 6/29/21 5/2/22 4/30/23 4/30/24
1EUR in Million
Estimates

Balance Sheet Analysis

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Net Debt 1 - - - - - -
Net Cash position 1 1.35 1.23 9.68 32.1 5.55 0.24
Leverage (Debt/EBITDA) - - - - - -
Free Cash Flow 1 -11.3 -6.03 -2.05 -3.7 -3.5 -0.51
ROE (net income / shareholders' equity) -606% -287% -88.7% -43.1% -7.54% -17.9%
ROA (Net income/ Total Assets) -85.2% -68.7% -20.6% -15.8% -7.76% -8.01%
Assets 1 12.65 10.98 29.78 75.11 45.74 109.2
Book Value Per Share - - - - - -
Cash Flow per Share - - - - - -
Capex 1 0.01 0 0.21 0.35 0.15 0.2
Capex / Sales 143.6% 2.47% 668.63% 1,547.6% 13,736.33% 37.79%
Announcement Date 4/29/19 4/30/20 6/29/21 5/2/22 4/30/23 4/30/24
1EUR in Million
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Sector Other Biotechnology & Medical Research

1st Jan change Capi.
MODERNA, INC. Stock Moderna, Inc.
+41.79% 54.04B
IQVIA HOLDINGS INC. Stock Iqvia Holdings Inc.
-0.56% 41.92B
LONZA GROUP AG Stock Lonza Group AG
+49.62% 41.96B
CELLTRION, INC. Stock Celltrion, Inc.
-7.20% 28.35B
ICON PUBLIC LIMITED COMPANY Stock ICON Public Limited Company
+12.59% 26.35B
ALNYLAM PHARMACEUTICALS, INC. Stock Alnylam Pharmaceuticals, Inc.
-21.51% 19B
BIO-TECHNE CORPORATION Stock Bio-Techne Corporation
+6.92% 13B
UNITED THERAPEUTICS CORPORATION Stock United Therapeutics Corporation
+24.91% 12.19B
MEDPACE HOLDINGS, INC. Stock Medpace Holdings, Inc.
+29.60% 12.28B
Other Biotechnology & Medical Research
  1. Stock Market
  2. Equities
  3. ALNEV Stock
  4. ALNEV Stock
  5. Financials NEOVACS
-40% Exceptional extension: Our subscriptions help you unlock the best investment opportunities.
BENEFIT NOW